Internal Medicine, Medical Oncology · San Antonio, TX
NPI
1700015625
Since 2009
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
8300 Floyd Curl Dr
San Antonio, TX, 78229
Phone (210) 450-1143
Groups this clinician bills Medicare through
Medicare paid, 2024
$644K
36,040 services
Medicare patients, 2024
268
Average age 73
Drug cost, 2024
$6.9M
736 prescriptions
Company payments, 2025
$75K
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zohra I Nooruddin was code J9271 (injection, pembrolizumab, 1 mg), 3,400 times for 11 patients. In total Zohra I Nooruddin billed 36,040 services in 102 codes, and Medicare paid $644K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-11-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 3,400 | 11 | $44.58 | $152K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,000 | 15 | $0.11 | $321 |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 1,786 | 28 | $2.24 | $3,995 |
| J0897 Injection, denosumab, 1 mg | Office | 1,740 | 13 | $19.93 | $35K |
| J9171 Injection, docetaxel, 1 mg | Office | 1,200 | 13 | $0.66 | $794 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 624 | 34 | $0.09 | $55.53 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 536 | 22 | $0.07 | $39.79 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 210 | 81 | $12.75 | $2,678 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 210 | 16 | $0.70 | $147 |
| J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | Office | 205 | 18 | $2.59 | $531 |
| 99214 Office E&M - Established | Office | 161 | 74 | $95.41 | $15K |
| 96375 Injection Administration | Office | 110 | 40 | $12.31 | $1,355 |
| 96413 Chemotherapy Administration | Office | 98 | 60 | $92.52 | $9,067 |
| 96367 Intravenous Infusion, Hydration | Office | 83 | 40 | $22.77 | $1,890 |
| 51720 Chemotherapy Administration | Office | 63 | 42 | $69.62 | $4,386 |
By year: 2022 $495K for 18,009 services; 2023 $534K for 26,902 services; 2024 $644K for 36,040 services.
Medicare prescription drug claims, 2024
In 2024, the drug Zohra I Nooruddin prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 88 prescriptions and refills. In total Zohra I Nooruddin wrote 736 Medicare prescriptions that cost $6.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 88 | 88 | 12 | $1.9M |
| Hydroxyurea Generic | 79 | 162 | 20 | $1,970 |
| Ojjaara Momelotinib Dihydrochloride | 50 | 50 | Under 11 | $1.5M |
| Levofloxacin Generic | 37 | 37 | Under 11 | $336 |
| Posaconazole Generic | 34 | 34 | Under 11 | $40K |
| Imatinib Mesylate Generic | 34 | 34 | Under 11 | $2,461 |
| Besremi Ropeginterferon Alfa-2b-Njft | 29 | 29 | Under 11 | $480K |
| Venclexta Venetoclax | 29 | 29 | Under 11 | $52K |
| Ayvakit Avapritinib | 27 | 27 | Under 11 | $1.0M |
| Valacyclovir Valacyclovir Hcl | 21 | 23 | Under 11 | $897 |
| Eliquis Apixaban | 20 | 20 | Under 11 | $12K |
| Pegasys Peginterferon Alfa-2a | 19 | 19 | Under 11 | $71K |
| Acyclovir Generic | 16 | 16 | Under 11 | $119 |
| Prochlorperazine Maleate Generic | 14 | 14 | Under 11 | $232 |
| Prednisone Generic | 14 | 14 | Under 11 | $22.94 |
Brand drugs: 365 claims; generic drugs: 371 claims; opioid claims: 14.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zohra I Nooruddin $75K ($74K in general payments such as food, travel and fees and $470 for research) from 9 companies. The largest payer was GlaxoSmithKline, LLC. with $69K.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 50 | $69K |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $3,159 |
| Celgene Corporation BMY | 3 | $1,668 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $470 |
| BeOne Medicines USA, Inc. ONC | 2 | $136 |
| Janssen Biotech, Inc. JNJ | 1 | $35.28 |
| Incyte Corporation INCY | 1 | $29.4 |
| Astellas Pharma US Inc 4503.T | 1 | $28.87 |
| Blueprint Medicines Corporation SNY | 1 | $22.4 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.